MARKET

ARCT

ARCT

Arcturus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.96
-0.23
-0.53%
After Hours: 43.60 +0.64 +1.49% 19:42 03/08 EST
OPEN
43.03
PREV CLOSE
43.19
HIGH
46.90
LOW
42.05
VOLUME
874.27K
TURNOVER
--
52 WEEK HIGH
129.71
52 WEEK LOW
8.51
MARKET CAP
1.13B
P/E (TTM)
-12.6984
1D
5D
1M
3M
1Y
5Y
Analyst Actions: B. Riley Lowers Arcturus Therapeutics' Price Target to $35 from $45 After Q4 2020 Earnings Miss Estimates, Keeps Sell Rating
MT Newswires · 20h ago
Ultragenyx Receives FDA Clearance of Investigational NDA for UX053 to Treat Glycogen Storage Disease Type III
MT Newswires · 22h ago
Arcturus Therapeutics (ARCT) Gets a Hold Rating from Raymond James
In a report released yesterday, Steven Seedhouse from Raymond James maintained a Hold rating on Arcturus Therapeutics (ARCT). The company's shares closed
SmarterAnalyst · 6d ago
DJ Arcturus Therapeutics Holdings Inc. CEO Joseph Payne on Q4 2020 Results -- Earnings Call Transcript >ARCT
Dow Jones · 03/02 02:47
Arcturus Therapeutics: Q4 Earnings Insights
Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 64.47% over the past year to ($1.25), which missed the estimate of ($0.88). Revenue of $2,238,0...
Benzinga · 03/01 22:26
10-K: ARCTURUS THERAPEUTICS HOLDINGS INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/01 21:57
BRIEF-Arcturus Therapeutics Posts Q4 Loss Per Share Of $1.25
reuters.com · 03/01 21:19
Arcturus Therapeutics EPS misses by $0.33, misses on revenue
Arcturus Therapeutics (ARCT): Q4 GAAP EPS of -$1.25 misses by $0.33.Revenue of $2.2M (-25.9% Y/Y) misses by $0.12M.Shares +3.7%.Press Release
Seekingalpha · 03/01 21:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARCT. Analyze the recent business situations of Arcturus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARCT stock price target is 87.31 with a high estimate of 160.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 188
Institutional Holdings: 19.85M
% Owned: 75.55%
Shares Outstanding: 26.28M
TypeInstitutionsShares
Increased
52
6.69M
New
69
-3.22M
Decreased
33
1.82M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Peter Farrell
President/Chief Executive Officer/Director
Joseph Payne
Chief Financial Officer/Director
Andrew Sassine
Chief Operating Officer/Chief Scientific Officer
Pad Chivukula
Vice President
Christine Esau
Chief Operating Officer/Chief Scientific Officer
Padmanabh Chivukula
Senior Vice President/Senior Principal
Kevin Skol
Other
Steven Hughes
Vice President - Finance/Controller
K. Kummerfeld
Director
Karah Parschauer
Independent Director
James Barlow
Vice President
Suezanne Parker
Independent Director
Edward Holmes
Independent Director
Magda Marquet
No Data
  • All
  • Financials
  • Insiders
More
About ARCT
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated delivery, STARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type three, hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for severe acute respiratory syndrome coronavirus two (SARS-CoV-2). Its RNA therapeutics platforms have applications in types of nucleic acid medicines, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, deoxyribonucleic acid (DNA) and gene editing therapeutics. The Company is focused on liver and respiratory diseases.

Webull offers kinds of Arcturus Therapeutics Holdings Inc stock information, including NASDAQ:ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.